Logo image
Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Journal article   Open access   Peer reviewed

Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation

Cheri A Pasch, Peter F Favreau, Alexander E Yueh, Christopher P Babiarz, Amani A Gillette, Joe T Sharick, Mohammad Rezaul Karim, Kwangok P Nickel, Alyssa K DeZeeuw, Carley M Sprackling, …
Clinical cancer research, Vol.25(17), pp.5376-5387
09/01/2019
DOI: 10.1158/1078-0432.ccr-18-3590
PMCID: PMC6726566
PMID: 31175091
url
https://doi.org/10.1158/1078-0432.ccr-18-3590View
Published (Version of record) Open Access

Abstract

Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predicts treatment sensitivity for individual patients is needed. Patient-derived cancer organoids were derived across multiple histologies. The histologic characteristics, mutation profile, clonal structure, and response to chemotherapy and radiation were assessed using bright-field and optical metabolic imaging on spheroid and single-cell levels, respectively. We demonstrate that patient-derived cancer organoids represent the cancers from which they were derived, including key histologic and molecular features. These cultures were generated from numerous cancers, various biopsy sample types, and in different clinical settings. Next-generation sequencing reveals the presence of subclonal populations within the organoid cultures. These cultures allow for the detection of clonal heterogeneity with a greater sensitivity than bulk tumor sequencing. Optical metabolic imaging of these organoids provides cell-level quantification of treatment response and tumor heterogeneity allowing for resolution of therapeutic differences between patient samples. Using this technology, we prospectively predict treatment response for a patient with metastatic colorectal cancer. These studies add to the literature demonstrating feasibility to grow clinical patient-derived organotypic cultures for treatment effectiveness testing. Together, these culture methods and response assessment techniques hold great promise to predict treatment sensitivity for patients with cancer undergoing chemotherapy and/or radiation.
Drug Screening Assays, Antitumor - methods Humans Microscopy, Fluorescence, Multiphoton - instrumentation Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - pathology Neoplasms - radiotherapy Organoids - drug effects Organoids - metabolism Organoids - pathology Organoids - radiation effects Precision Medicine - methods Spheroids, Cellular - drug effects Spheroids, Cellular - metabolism Spheroids, Cellular - radiation effects

Details

Metrics

Logo image